Clinical Ink Acquires Digital Artefacts

Clinical Ink, a global clinical trial data and technology company and leader in eSource and decentralized clinical trial conduct, today announced its acquisition of Digital Artefacts, a digital endpoint-based technology company with an unrivaled modular platform for complex cognitive, behavioral, and physiological data capture.

“The addition of Digital Artefacts now allows us to drive situational awareness because context matters. Data derived from Digital Artefacts can now increase the richness of our partners’ study data through the convergence of passive and active digital assessments. Their wearables and sensors acumen provides instrumented data collection that complements our existing products and solutions,” said Clinical Ink CEO Ed Seguine. “It continues our commitment to capture data at the source and deliver quantitative insights, empowering our customers to make real-time highly informed decisions.”

The combination of Clinical Ink and Digital Artefacts will provide benefits including:

  • Scientifically validated neurocognitive assessment and research tools (50+ modular, self-administered assessments)
  • Combination of standardized eCOA scales/assessments with novel digital endpoints to produce quantitative patient outcomes
  • Trial specific remote active and passive behavioral assessment, including wearable and sensor data
  • Precision Real-World Data and insights across complex therapeutic areas for which cognition is an endpoint
  • Expertise in creating clinically relevant novel digital endpoint data collection methodologies including voice, movement, behavior, mood, and other real-world measurements
  • Scaled delivery capabilities in logistics, helpdesk, project management, and device acquisition/support for DCTs

These capabilities reinforce Clinical Ink’s reputation as a trusted, global partner in digital source data capture (DDC) and eCOA, furthering the company’s therapeutic-area-specific approach to study design and data certainty from source to submission.

“Our digital endpoint solutions, combined with strong data science, provide expertise that has been foundational with industry recognized partners and top pharma,” noted Joan Severson, co-founder, president, and general manager of Digital Artefacts. “We are very excited to join Clinical Ink and enhance the seamless data collection, cognitive and behavioral assessments, and quantitative outcomes for even the most complex studies.”

With this acquisition, Clinical Ink continues to be the leading partner for decentralized clinical trials with a complete, configurable digital data platform — the only partner equipped to build studies for specific trial needs.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.